<DOC>
	<DOCNO>NCT01447862</DOCNO>
	<brief_summary>Atrial fibrillation common cardiac arrhythmia expect affect 30 million North Americans Europeans 2050 . Atrial fibrillation associate increase cardiovascular morbidity mortality , stroke especially important potentially devastating complication . Many study investigate efficacy different drug convert atrial fibrillation sinus rhythm . There numerous randomize controlled trial test efficacy agent placebo trial directly compare efficacy two different drug . The class III antiarrhythmic drug Ibutilde approve acute termination atrial fibrillation atrial flutter recent onset show superior sotalol equivalent flecainide indication . Recently , relatively atrial selective antiarrhythmic agent vernakalant approve European Commission rapid conversion recent onset AF sinus rhythm adult . The investigator hypothesize period time need cardioversion sinus rhythm efficacy cardioversion within 90 minute different vernakalant ibutilide patient recent-onset atrial fibrillation .</brief_summary>
	<brief_title>Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Ibutilide</mesh_term>
	<criteria>Symptoms atrial fibrillation since long 48 hour Age 18 90 year Need immediate electrical cardioversion due hemodynamic instability ( hypotension : systolic blood pressure &lt; 100 mmHg , dyspnea , loss consciousness , unstable angina ) Moderate severe heart failure ( NYHA III/IV ) patient previously document leave ventricular ejection fraction ( LVEF ) ≤ 35 % History sign acute coronary syndrome ( acute myocardial infarction , unstable angina ) within last 30 day Resting ventricular rate &lt; 80 beat per minute without pace maker backup QT interval &gt; 440 millisecond WolffParkinsonWhite ( WPW ) syndrome History Torsade de point arrhythmias polymorphic ventricular tachycardia Signs thyreotoxicosis Sick Sinus Syndrome atrioventricular block great first degree Severe valvular heart disease , clinically meaningful hypertrophic obstructive cardiomyopathy , restrictive cardiomyopathy , constrictive pericarditis Serious disorder hepatic , renal ( Creatinine &gt; 2.5mg/dl ) , pulmonary , gastrointestinal , hematologic central nervous system serious psychiatric disorder Abnormal serum electrolytes despite adequate therapy ( especially potassium &lt; 3.5 mmol/l &gt; 5.5 mmol/l ) Intravenous use Class I III antiarrythmic drug within 4 hour study drug application Pregnancy ( βHCG test perform female subject apart woman &gt; 50 year amenorrhea least 12 month ( absence cause amenorrhoea ) Known hypersensitivity study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>recent-onset</keyword>
</DOC>